Non Small Cell Lung Cancer Clinical Trials in Chapel Hill, North Carolina

11 studies are recruiting for non small cell lung cancer in Chapel Hill, North Carolina right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

   Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Clinical Study Site, Chapel Hill, North Carolina

   Locations

   285 in total

   Run by

   Summit Therapeutics

   See if you can join NCT06767514 on ClinicalTrials.gov

2. A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

   Researchers are looking for new ways to treat high-risk, localized non-small cell lung cancer (NSCLC) that has been removed with surgery. People with high-risk, localized NSCLC are often treated with surgery. Researchers want to learn if participants can receive 1 or 2 trial treatments to help prev…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   UNC Lineberger Comprehensive Cancer Center ( Site 3250), Chapel Hill, North Carolina

   Locations

   93 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT07513376 on ClinicalTrials.gov

3. Effects of Infusion Timing on Treatment Response in Solid Tumors

   This study evaluates whether the time of day when immunotherapy is given affects clinical outcomes. It includes patients eligible for PD-1 (programmed cell death protein 1) or PD-L1 (programmed death-ligand 1) inhibitor treatment who have either advanced or metastatic non-small cell lung cancer (NS…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of North Carolina at Chapel Hill, Department of Radiation Oncology, Chapel Hill, North Carolina

   Run by

   UNC Lineberger Comprehensive Cancer Center

   See if you can join NCT07630168 on ClinicalTrials.gov

4. ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

   The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors. It is necessary that ctDNA test results are linked to clinical outcomes in order to demonstrate clinical validity for rec…

   Stage

   Not phased

   Ages

   18 and older

   Site

   UNC- Chapel Hill, Chapel Hill, North Carolina

   Locations

   57 in total

   Run by

   Guardant Health, Inc.

   See if you can join NCT05059444 on ClinicalTrials.gov

5. Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

   This is a Phase 1, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid tumor malignancy with homozygous deletion of the MTAP gene.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of North Carolina - Gastroenterology and Hepatology, Chapel Hill, North Carolina

   Locations

   25 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT05245500 on ClinicalTrials.gov

6. Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

   The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to docetaxel.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   UNC Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill, North Carolina

   Locations

   153 in total

   Run by

   Revolution Medicines, Inc.

   See if you can join NCT06881784 on ClinicalTrials.gov

7. Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

   This is a Phase 3 Randomized, double-blind, Multiregional Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer. The primary endpoint is overall survival and progression free survival ass…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   University of North Carolina, Chapel Hill, North Carolina

   Locations

   260 in total

   Run by

   Summit Therapeutics

   See if you can join NCT05899608 on ClinicalTrials.gov

8. JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer

   To Determine if SAbR improves survival over SR in High Risk Operable Stage I NSCLC

   Stage

   Phase 3

   Ages

   18 and older

   Site

   University of North Carolina, Chapel Hill, North Carolina

   Locations

   50 in total

   Run by

   University of Texas Southwestern Medical Center

   See if you can join NCT02468024 on ClinicalTrials.gov

9. GEMINI-NSCLC: NSCLC Biomarker Study

   GEMINI NSCLC Study is a non-interventional study that will be collecting clinical and molecular health information from patients with NSCLC who will receive longitudinal blood collection in addition to their standard of care therapy and disease surveillance with the goals of identifying the molecul…

   Stage

   Not phased

   Ages

   18 and older

   Site

   UNC, Chapel Hill, North Carolina

   Locations

   58 in total

   Run by

   Tempus AI

   See if you can join NCT05236114 on ClinicalTrials.gov

10. Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer

    This is a phase 1, single-center, open-label study that enrolls adult subjects with extensive stage lung cancer or stage IV non-small cell lung cancer that is platinum-refractory and received PD-1 and/or PD-L1 therapy. The purpose of this study is to test the safety of using a new treatment called …

    Stage

    EARLY_Phase 1

    Ages

    18 and older

    Site

    Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina

    Run by

    UNC Lineberger Comprehensive Cancer Center

    See if you can join NCT05620342 on ClinicalTrials.gov

11. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

    International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical…

    Stage

    Not phased

    Ages

    Any age

    Site

    Massive Bio SYNERGY-AI site, Chapel Hill, North Carolina

    Locations

    68 in total

    Run by

    Massive Bio, Inc.

    See if you can join NCT03452774 on ClinicalTrials.gov